Trials / Completed
CompletedNCT00731185
Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)
A Multi-center, Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety of Mometasone Furoate Nasal Spray (MFNS) in the Post Surgical Treatment of Nasal Polyposis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was conducted to evaluate the effectiveness of mometasone nasal spray in preventing polyp relapse/symptom worsening in patients after surgical treatment of nasal polyps. Patients who met Screening eligibility underwent endoscopic sino-nasal surgery (FESS) on visit 2. Mometasone nasal spray or placebo was started about 2 weeks after surgery and continued for up to 24 weeks or until relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone Furoate Nasal Spray | MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse |
| DRUG | Placebo |
Timeline
- Start date
- 2003-09-01
- Primary completion
- 2005-09-01
- Completion
- 2005-09-01
- First posted
- 2008-08-08
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00731185. Inclusion in this directory is not an endorsement.